AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35913657 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate variability (HRV) analysis measured prior to the induction of anaesthesia and immediately before eyeball traction.
Number of subjects: 52
Study 35913657 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial ANS tone assessment based on frequency domain HRV parameters from 5-min Holter electrocardiogram recordings.
Number of subjects: 52
Study 35913657 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial heart rate, blood pressure, age, sex, and ASA status.
Number of subjects: 52
Study 35913883 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic immediacy events initiated by therapists
Number of subjects: 4
Study 35913883 — intervention group
Group type: EXPERIMENTAL
Intervention: Good outcome cases
Number of subjects: 4
Study 35913883 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor outcome cases
Number of subjects: 4
Study 35913883 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency and rated quality of immediacy events
Number of subjects: 4
Study 35914096 — intervention group
Group type: EXPERIMENTAL
Intervention: Base-in prism (n = 22)
Number of subjects: 57
Study 35914096 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision therapy/exercises (n = 35)
Number of subjects: 57
Study 35914096 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 57
Study 35914222 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose apixaban (2.5 mg twice daily)
Number of subjects: 732
Study 35914222 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulation (D-dimer negative patients)
Number of subjects: 732
Study 35914226 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19-CARCD7- T cells
Number of subjects: 0
Study 35914226 — intervention group
Group type: COMPARATOR
Intervention: Bulk CD19-CAR T cells
Number of subjects: 0
Study 35914226 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19-CARCD7lo T cells
Number of subjects: 0
Study 35914227 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplant with gene therapy (ASCT-GT)
Number of subjects: 10
Study 35914227 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 10
Study 35914239 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin/cyclophosphamide (A/C) followed by paclitaxel for neoadjuvant systemic therapy (NAST)
Number of subjects: 56
Study 35914239 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologically based model using MRI data
Number of subjects: 56
Study 35914239 — intervention group
Group type: COMPARATOR
Intervention: Tumor volume measured after four cycles of A/C
Number of subjects: 56
Study 35914538 — intervention group
Group type: EXPERIMENTAL
Intervention: ReStoreD: Promoting Resilience after Stroke in Dyads (8-week self-administered dyadic positive psychology intervention)
Number of subjects: 26
Study 35914576 — intervention group
Group type: EXPERIMENTAL
Intervention: IFAB-Turkish version (IFAB-Tr)
Number of subjects: 93
Study 35914576 — intervention group
Group type: COMPARATOR
Intervention: Health Assessment Questionnaire (HAQ)
Number of subjects: 93
Study 35914576 — intervention group
Group type: COMPARATOR
Intervention: Hospital Anxiety and Depression Scale (HADS)
Number of subjects: 93
Study 35914576 — intervention group
Group type: COMPARATOR
Intervention: Bath Ankylosing Spondylitis Functional Index (BASFI)
Number of subjects: 93
Study 35914905 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green clearance test (IGT) administered to the donor, with a cut-off value of 13% for plasma disappearance rate (PDR).
Number of subjects: 162
Study 35914905 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green clearance test (IGT) measured at different time-points in the LT recipient: during the anhepatic phase, after graft reperfusion, at 24 hours, on day 3 and day 7 after LT.
Number of subjects: 162
Study 35915019 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9 levels measured at baseline and after 5 days (ng/ml)
Number of subjects: 74
Study 35915019 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate of apoptosis (AR) of human umbilical vein endothelial cells incubated with patients' serum
Number of subjects: 74
Study 35915019 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of PCSK9 in patients
Number of subjects: 74
Study 35915019 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day change of PCSK9
Number of subjects: 74
Study 35915020 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 17259
Study 35915020 — intervention group
Group type: COMPARATOR
Intervention: No Radiotherapy (Control)
Number of subjects: 17259
Study 35915020 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine Therapy
Number of subjects: 17259
Study 35915020 — intervention group
Group type: EXPERIMENTAL
Intervention: Black Race
Number of subjects: 17259
Study 35915020 — intervention group
Group type: EXPERIMENTAL
Intervention: Private Insurance
Number of subjects: 17259
Study 35915020 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥ 70 years
Number of subjects: 17259
Study 35915020 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor size > 20 mm
Number of subjects: 17259
Study 35915020 — intervention group
Group type: EXPERIMENTAL
Intervention: CDCC score > 0
Number of subjects: 17259
Study 35915157 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab (anti-EGFR monoclonal antibody)
Number of subjects: 52
Study 35915157 — intervention group
Group type: COMPARATOR
Intervention: Standard third-line treatments
Number of subjects: 52
Study 35915181 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 78
Study 35915419 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy (ET) initiation by 12-month interview
Number of subjects: 533
Study 35915419 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy (ET) continuation for ≥12 months by 24-month interview
Number of subjects: 533
Study 35915419 — intervention group
Group type: COMPARATOR
Intervention: Diabetes status
Number of subjects: 533
Study 35915419 — intervention group
Group type: COMPARATOR
Intervention: Menopausal-symptom severity
Number of subjects: 533
Study 35915479 — intervention group
Group type: EXPERIMENTAL
Intervention: Residence-Based Testing Participation Pilot (RB-TPP)
Number of subjects: 464
Study 35602670 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligometastatic treatment
Number of subjects: 0
Study 35602670 — intervention group
Group type: COMPARATOR
Intervention: Polymetastatic treatment
Number of subjects: 0
Study 35915738 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI)
Number of subjects: 0
Study 35915738 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy with fluticasone furoate/vilanterol (FF/VI)
Number of subjects: 0
Study 35915738 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy with umeclidinium/vilanterol (UMEC/VI)
Number of subjects: 0
Study 35915749 — intervention group
Group type: EXPERIMENTAL
Intervention: GuttaFlow2
Number of subjects: 0
Study 35915749 — intervention group
Group type: EXPERIMENTAL
Intervention: GuttaCore
Number of subjects: 0
Study 35915749 — intervention group
Group type: COMPARATOR
Intervention: Cold lateral compaction (CLC)
Number of subjects: 0
Study 35915749 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold free-flow compaction (GuttaFlow2)
Number of subjects: 0
Study 35916001 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-assessment of core strength and endurance tests (Curl-up, Modified Push-up, Plank, Lateral Bridge)
Number of subjects: 80
Study 35916001 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-assessment of functional capacity tests (Timed Up and Go, 30 second Sit to Stand, Functional Reach Test)
Number of subjects: 80
Study 35916001 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-assessment method
Number of subjects: 80
Study 35916001 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-assessment of core strength-endurance and functional tests
Number of subjects: 80
Study 35916675 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispersion slope (DS) measurements from 2D shear-wave elastography (SWE)
Number of subjects: 159
Study 35916675 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver stiffness (LS) measurements from 2D shear-wave elastography (SWE)
Number of subjects: 159
Study 35916675 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of DS and LS measurements from 2D shear-wave elastography (SWE)
Number of subjects: 159
Study 35916679 — intervention group
Group type: EXPERIMENTAL
Intervention: VERDICT MRI analysis
Number of subjects: 303
Study 35916679 — intervention group
Group type: EXPERIMENTAL
Intervention: mpMRI-derived apparent diffusion coefficient (ADC)
Number of subjects: 303
Study 35916679 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate-specific antigen density (PSAD)
Number of subjects: 303
Study 35916685 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensated cirrhosis
Number of subjects: 87
Study 35916685 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompensated cirrhosis
Number of subjects: 87
Study 35916685 — intervention group
Group type: EXPERIMENTAL
Intervention: HRS-AKI
Number of subjects: 87
Study 35916685 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 87
Study 35916686 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor air quality monitor and home spirometer to measure VOCs and PM
Number of subjects: 50
Study 35916707 — intervention group
Group type: EXPERIMENTAL
Intervention: iQuit Mindfully text messages
Number of subjects: 0
Study 35916707 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness videoconference groups
Number of subjects: 0
Study 35916707 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of iQuit Mindfully text messages and mindfulness videoconference groups
Number of subjects: 0
Study 35916707 — intervention group
Group type: COMPARATOR
Intervention: No iQuit Mindfully text messages
Number of subjects: 0
Study 35916707 — intervention group
Group type: COMPARATOR
Intervention: No mindfulness videoconference groups
Number of subjects: 0
Study 35916981 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter drainage
Number of subjects: 72
Study 35916981 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting catheter-drainage failure
Number of subjects: 72
Study 35917057 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg
Number of subjects: 50
Study 35917057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 35917174 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Exercise Program (SEP)
Number of subjects: 166
Study 35917174 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-Based Structured Exercise Program (HSEP)
Number of subjects: 166
Study 35917174 — intervention group
Group type: COMPARATOR
Intervention: Walk Advice (WA)
Number of subjects: 166
Study 35917659 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-occurring anxiety symptoms
Number of subjects: 216
Study 35917659 — intervention group
Group type: COMPARATOR
Intervention: Hostility/anger
Number of subjects: 216
Study 35917659 — intervention group
Group type: COMPARATOR
Intervention: Trait positive affect
Number of subjects: 216
Study 35917778 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35917829 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 394
Study 35917829 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 394
Study 35918160 — intervention group
Group type: EXPERIMENTAL
Intervention: β-amyloid positivity
Number of subjects: 921
Study 35918160 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical thickness in medial temporal lobe structures
Number of subjects: 921
Study 35918160 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroinflammation
Number of subjects: 921
Study 35918160 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociodemographic factors
Number of subjects: 921
Study 35918160 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale (HADS) assessment
Number of subjects: 921
Study 35918190 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioinfusions
Number of subjects: 0
Study 35918190 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention observational expectant management
Number of subjects: 0
Study 35918231 — intervention group
Group type: EXPERIMENTAL
Intervention: AYAs reported navigating openness and closedness about LFS in their families, which varied by LFS topic, relationship, disease trajectory, and developmental phase.
Number of subjects: 38
Study 35918231 — intervention group
Group type: EXPERIMENTAL
Intervention: AYAs reported experiencing LFS family communication challenges that disrupted their psychosocial well-being.
Number of subjects: 38
Study 35918246 — intervention group
Group type: EXPERIMENTAL
Intervention: EAT-Lancet diet adherence (measured by EAT-Lancet Diet Index, ELD-I)
Number of subjects: 62382
Study 35918246 — intervention group
Group type: EXPERIMENTAL
Intervention: EAT-Lancet diet adherence (measured by ELD-I) among low drinkers
Number of subjects: 62382
Study 35918246 — intervention group
Group type: EXPERIMENTAL
Intervention: EAT-Lancet diet adherence (measured by ELD-I) among females
Number of subjects: 62382
Study 35918666 — intervention group
Group type: EXPERIMENTAL
Intervention: No-cost contraception (April 2016-March 2017)
Number of subjects: 1029
Study 35918666 — intervention group
Group type: COMPARATOR
Intervention: Control period with no reduction in cost for the contraceptive implant, reduced price for hormonal IUD, sliding scale for copper IUD (September 2015-March 2016)
Number of subjects: 1029
Study 35918683 — intervention group
Group type: EXPERIMENTAL
Intervention: New light rail transit (LRT) line
Number of subjects: 0
Study 35918685 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-mortem magnetic resonance imaging with computed tomography-guided biopsy (Virtopsy®)
Number of subjects: 101
Study 35918685 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography-guided tissue sampling
Number of subjects: 101
Study 35918703 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-level hypertension control program including a hypertension patient registry, performance and quality reporting, simplified treatment guidelines, access to essential medicines, team-based care, health coaching, and home blood pressure monitoring.
Number of subjects: 60
Study 35918703 — intervention group
Group type: COMPARATOR
Intervention: Control phase of sequential registration and empanelment of hypertensive patients at participating primary healthcare centers.
Number of subjects: 60
Study 35918719 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary assessment including respiratory assessment, muscular evaluation, psychopathological evaluation, and quality of life
Number of subjects: 62
Study 35918722 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculin skin testing (TST) or interferon gamma release assay (IGRA) for TB infection (TBI) followed by chest X-Ray (CXR) to rule out TB disease (TBD) if positive
Number of subjects: 0
Study 35918722 — intervention group
Group type: EXPERIMENTAL
Intervention: GeneXpert (GX) replaces CXR after TST or IGRA for TBI
Number of subjects: 0
Study 35918722 — intervention group
Group type: COMPARATOR
Intervention: No TBI testing, CXR for all; if CXR is normal, TPT is recommended
Number of subjects: 0
Study 35918734 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term educational intervention on complementary feeding (CF) provided by community health workers (CHWs).
Number of subjects: 360
Study 35918734 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term educational intervention on complementary feeding (CF).
Number of subjects: 360
Study 35918734 — intervention group
Group type: COMPARATOR
Intervention: Existing healthcare services (comparison group).
Number of subjects: 360
Study 35918743 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) injections, mean number of injections by Month 12: 3.7 ± 1.8 (treatment-naïve), 4.0 ± 2.2 (previously treated).
Number of subjects: 258
Study 35918757 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular therapy (VT) for 8 weeks, ~25-min office sessions with a vestibular therapist
Number of subjects: 100
Study 35918757 — intervention group
Group type: COMPARATOR
Intervention: Active control therapy for 8 weeks
Number of subjects: 100
Study 35919026 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning model for locating the interscalene brachial plexus in ultrasound images
Number of subjects: 1126
Study 35919026 — intervention group
Group type: COMPARATOR
Intervention: Nonexpert anaesthesiologists
Number of subjects: 1126
Study 35919065 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low dose computed tomography (ULD-CT)
Number of subjects: 76
Study 35919065 — intervention group
Group type: COMPARATOR
Intervention: Digital radiography
Number of subjects: 76
Study 35919265 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 94
Study 35919268 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency intermittent fasting regimen
Number of subjects: 0
Study 35919345 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty assessed by CFS (frail group)
Number of subjects: 263
Study 35919345 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-frail assessed by CFS
Number of subjects: 263
Study 35919345 — intervention group
Group type: EXPERIMENTAL
Intervention: Robust assessed by CFS
Number of subjects: 263
Study 35919345 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty assessed by Fried criteria (frail group)
Number of subjects: 263
Study 35919345 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-frail assessed by Fried criteria
Number of subjects: 263
Study 35919345 — intervention group
Group type: EXPERIMENTAL
Intervention: Robust assessed by Fried criteria
Number of subjects: 263
Study 35919538 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary CCL14 cutoff of 1.3 ng/ml
Number of subjects: 0
Study 35919538 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary CCL14 cutoff of 13 ng/ml
Number of subjects: 0
Study 35919538 — intervention group
Group type: EXPERIMENTAL
Intervention: CCL14 concentration between 1.3 and 13 ng/ml
Number of subjects: 0
Study 35919662 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial risk information (graphical representation of atherosclerosis)
Number of subjects: 3000
Study 35919662 — intervention group
Group type: COMPARATOR
Intervention: Control group (without intervention)
Number of subjects: 3000
Study 35919766 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight Control (TC) management with TNFi dose changes informed by biochemical markers of inflammation
Number of subjects: 0
Study 35919766 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight Control (TC) management
Number of subjects: 0
Study 35919766 — intervention group
Group type: COMPARATOR
Intervention: Conventional Management (CM)
Number of subjects: 0
Study 35920161 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 1279
Study 35920161 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education
Number of subjects: 1279
Study 35920743 — intervention group
Group type: EXPERIMENTAL
Intervention: elbasvir (50 mg)/grazoprevir (100 mg)
Number of subjects: 301
Study 35920743 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 301
Study 35920783 — intervention group
Group type: EXPERIMENTAL
Intervention: NC-6300 (Nanoparticle Epirubicin) at a dose of 150 mg/m2 intravenously (IV) once every 3 weeks
Number of subjects: 10
Study 35920783 — intervention group
Group type: EXPERIMENTAL
Intervention: NC-6300 (Nanoparticle Epirubicin)
Number of subjects: 10
Study 35920839 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Support System
Number of subjects: 0
Study 35920968 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (US)
Number of subjects: 100
Study 35921139 — intervention group
Group type: EXPERIMENTAL
Intervention: Secure Messaging for Medication Reconciliation Tool (SMMRT)
Number of subjects: 20
Study 35921449 — intervention group
Group type: EXPERIMENTAL
Intervention: L9LS administered intravenously or subcutaneously at doses of 1 mg, 5 mg, or 20 mg per kilogram of body weight
Number of subjects: 0
Study 35921449 — intervention group
Group type: COMPARATOR
Intervention: Control participants (not specified)
Number of subjects: 0
Study 35921541 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax
Number of subjects: 38
Study 35921541 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib added to Venetoclax
Number of subjects: 38
Study 35921541 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib continued
Number of subjects: 38
Study 35921541 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax ± Ibrutinib
Number of subjects: 38
Study 35921627 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with simulated patients
Number of subjects: 1113
Study 35921627 — intervention group
Group type: COMPARATOR
Intervention: Regular training (control group)
Number of subjects: 1113
Study 35921627 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (simulated patient and control)
Number of subjects: 1113
Study 35921685 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth system alerts for high risk of ED visits
Number of subjects: 206
Study 35921685 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth system usability
Number of subjects: 206
Study 35921693 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive development assessment using Bayley Scales at 6, 12, 24, and 36 months
Number of subjects: 580
Study 35921693 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor development assessment using Bayley Scales at 6, 12, 24, and 36 months
Number of subjects: 580
Study 35921693 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive, motor and behavioral outcomes using Movement Assessment Battery for Children and Child Behavior Checklist for Ages 1.5-5 at 4 years of age
Number of subjects: 580
Study 35921817 — intervention group
Group type: EXPERIMENTAL
Intervention: CD24Fc treatment
Number of subjects: 0
Study 35921817 — intervention group
Group type: COMPARATOR
Intervention: Inactivation of the CD24-Siglec-E pathway
Number of subjects: 0
Study 35922062 — intervention group
Group type: EXPERIMENTAL
Intervention: eSkinHealth app
Number of subjects: 0
Study 35922062 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0